Regenerx Biopharmaceuticals Inc RGRX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $0.00
- Day Range
- $0.00–0.00
- 52-Week Range
- $0.00–4.00
- Bid/Ask
- — / —
- Market Cap
- $2,095.75
- Volume/Avg
- 2,518 / 442
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Regenerx Biopharmaceuticals Inc is focused on the discovery and development of novel molecules to accelerate tissue and organ repair. Its operations are confined to one business segment: the development and marketing of product candidates based on Thymosin Beta 4 (Tß4), an amino acid peptide. The company has formulated Tß4 into three distinct product candidates in clinical development: RGN-259, a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease or other pathology; RGN-137, a topical gel for dermal wounds and reduction of scar tissue; and RGN-352, an injectable formulation to treat cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications that may be treated by systemic administration.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 3
- Website
- https://www.regenerx.com
Valuation
|
Metric
|
RGRX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
RGRX
Financial Strength
|
Metric
|
RGRX
|
|---|---|
Quick Ratio | 0.06 |
Current Ratio | 0.07 |
Interest Coverage | −4.19 |
Quick Ratio
RGRX
Profitability
|
Metric
|
RGRX
|
|---|---|
Return on Assets (Normalized) | −206.96% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
RGRX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk A/S ADR
NVO
| Lfgnthcmg | Qyn | $565.6 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Lwgczmsg | Mbrzgy | $127.8 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Mkwcnvww | Hyhnzst | $118.7 Bil | |||
| Moderna Inc
MRNA
| Rttvybgmc | Bxzx | $46.8 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Fgwpmjsg | Mtmxfd | $29.7 Bil | |||
| argenx SE ADR
ARGX
| Tkdkzdpl | Jxrc | $29.3 Bil | |||
| BioNTech SE ADR
BNTX
| Xztrrkrn | Wbbx | $20.7 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Kmkycrzp | Lkgyhnt | $16.1 Bil | |||
| United Therapeutics Corp
UTHR
| Gcgfqyf | Krrkb | $15.0 Bil | |||
| Incyte Corp
INCY
| Fbfzjgqww | Jsnqbr | $13.5 Bil |